QuarterHawk — Equity ResearchQuarterHawk — Equity Research

Mobia Medical, Inc. Common Stock (MOBI)

Healthcare

No action
Fundamental
2
Sentiment
3
Technical
4

Do Nothing: fundamentalScore 2 is below the required floor of 3 and 20-session average dollar volume of $2,310,358 is under the $5,000,000 liquidity floor; neither a pullback limit nor a breakout stop is admissible while these hard blocks hold.

Analysis as of 2026-11-15· more than 2 trading days ago

Company overview

Mobia Medical, Inc. develops neurostimulation medical devices, including the FDA-approved Vivistim System for stroke rehabilitation. The company focuses on combining vagus nerve stimulation with therapy to address chronic neurological conditions.

Fundamental

weak
Fundamental2
Weak fundamentals

Mobia Medical shows rapid revenue growth but remains deeply unprofitable with no earnings-based valuation support.

Rapid-growth but deeply unprofitable single-product medtech. Revenue is compounding hard (+104.8% in FY2025, +93.0% for nine-month 2026, with FY2026 revenue guidance raised to $57.0-57.5M) on an 82.57% gross margin, and the post-IPO balance sheet is strong: $160.69M cash, $8.37M total debt, current ratio 11.79x, going-concern doubt cleared and all debt covenants in compliance with no principal due before 2028. But trailing net income is about -$70.06M with -$59.70M of operating cash flow and -$61.44M of free cash flow, there is no earnings-based valuation support (P/E -6.27, EV/EBITDA -4.35), both DCF models are unusable, the reported free float is only about 6.19% and the IPO lock-up expired around 3 November 2026 with roughly 22.0M registered shares. Analyst Buy/Overweight ratings with a $25.50 consensus target and a director/officer insider-buying cluster are the main offsets. Weak-to-mixed and speculative; best treated as a watchlist name rather than a fundamentals-supported entry.

Sentiment

fair
Sentiment3
Mixed sentiment

Sentiment is two-sided with positive media coverage offset by a significant lock-up expiry.

Dominant in-window catalyst is the 2026-11-05 Q3-2026 release (confidence: announced) — a $15.6M revenue quarter (+73% y/y) and a raised FY2026 revenue guide offset by a wider net loss and same-window coverage attributing share pressure to the slowing-growth framing, so it reads as a wash rather than a bullish leg — set against a ~22.0M-share lock-up expiry around 2026-11-03 (bearish supply overhang) and a post-print BTIG Buy reiteration with the target lifted to $20. Media sentiment improved from a +0.154 baseline to +0.36 in the scoring window (determinate but thin: two scored items after five extraction failures); the Red-Flag Screen is clean on every severe test, but a moderate "conflicting catalyst signals" flag fired, capping the read at the moderate ceiling.

Technical

good
Technical4
Bullish trend

The stock is in a bullish trend with strong momentum indicators, but liquidity constraints limit trading opportunities.

The chart itself is genuinely bullish: price 13.17 sits above the SMA20 (11.11), SMA50 (10.13), EMA9 (12.27) and EMA21 (11.30) and essentially on the daily VWAP (13.17), MACD (0.87/0.59) is positive with an expanding +0.29 histogram, ADX14 27.83 is above 25 and rising, and RSI14 68.83 confirms strong momentum into the 2026-11-12 high of 13.60. But the move is extended — +64% off the 2026-10-19 low of 8.03 in 18 sessions and 18.5% above the 20-day — and the last three sessions stalled between 12.64 and 13.60 with Williams %R already at -11.75. Chart quality scores 4, yet no trade is admissible: fundamentalScore 2 is below the required floor of 3 and 20-session average dollar volume of ~$2.31M is under the $5M liquidity floor.

You’re looking at 2026-11-15 — more than 2 trading days ago.

Subscribers saw this then, and see today’s score, verdict and trade plan now.

Not financial advice. For informational and educational purposes only.